Posted on September 1, 2021 by Florian Buschek
INmune Bio INMB (Disclosure: long) came out after hours with a press release regarding the long awaited Phase 1 data of XPro™ in Alzheimer’s patients. The stock rightfully gapped up after hours while still being dramatically undervalued as compared to publicly traded comps on their AD treatment alone and their NK program could be worth many times the current market cap on top.
XPro™ treatment shows statistically significant decrease in Phospho Tau 217 (pT271) and pT181, and an improvement in an imaging biomarker of myelination.
These biomarker data are from the analysis of the Company’s recently concluded Phase 1 study of XPro™ in Alzheimer’s patients. AD patients treated with 1.0 mg/kg of XPro™ once a week for three months had a 46% reduction is CSF pT217 (p<0.0001) and a lesser reduction in pT181 (p<0.01). While pT181 is recognized as the standard CSF biomarker of AD, recent studies suggest that pT217 has higher discriminative accuracy for AD and a stronger correlation with amyloidosis and cognitive decline.
A more detailed webinar will happen as well:
Investor Webinar Details
Date: September 7, 2021
Time: 4:30 pm ET
Registration Link: (Click Here) or: https://us06web.zoom.us/webinar/register/WN_IlMwrkPGRa63319QM91YFg
Breakout investors were again ahead of the curve, just recently we released our ten minutes on the company where I chatted with Ashleigh and Scott. For more research, check out Ashleigh’s room on the Breakout Investor Platform.
Huge kudos also to Dan Carlson who has been involved for a lot longer and provides excellent coverage and research.